186 related articles for article (PubMed ID: 29868473)
1. Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.
Kunos CA; Ivy SP
Front Oncol; 2018; 8():149. PubMed ID: 29868473
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.
Kunos CA; Andrews SJ; Moore KN; Chon HS; Ivy SP
Front Oncol; 2019; 9():1067. PubMed ID: 31681600
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.
Kunos CA; Sherertz TM
Front Oncol; 2014; 4():184. PubMed ID: 25105092
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.
Kunos CA; Chu E; Makower D; Kaubisch A; Sznol M; Ivy SP
Front Oncol; 2017; 7():62. PubMed ID: 28421163
[TBL] [Abstract][Full Text] [Related]
6. Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.
Feng Y; Kunos CA; Xu Y
Biomed Chromatogr; 2015 Sep; 29(9):1380-7. PubMed ID: 25677991
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Dunst J; Haensgen G
Strahlenther Onkol; 2001 Dec; 177(12):635-40. PubMed ID: 11789401
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiation: A new approach for the treatment of cervical cancer.
Loizzi V; Cormio G; Loverro G; Selvaggi L; Disaia PJ; Cappuccini F
Int J Gynecol Cancer; 2003; 13(5):580-6. PubMed ID: 14675339
[TBL] [Abstract][Full Text] [Related]
10. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
[TBL] [Abstract][Full Text] [Related]
11. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
13. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
14. Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.
Segovia-Mendoza M; Jurado R; Mir R; Medina LA; Prado-Garcia H; Garcia-Lopez P
BMC Cancer; 2015 Jan; 15():21. PubMed ID: 25622528
[TBL] [Abstract][Full Text] [Related]
15. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Haie-Meder C; Fervers B; Chauvergne J; Fondrinier E; Lhommé C; Guastalla JP; Resbeut M
Bull Cancer; 1999 Oct; 86(10):829-41. PubMed ID: 10572234
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer.
Eifel PJ
Nat Clin Pract Oncol; 2006 May; 3(5):248-55. PubMed ID: 16683003
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality therapy of locally advanced cervical cancer.
Rose PG
J Clin Oncol; 2003 May; 21(10 Suppl):211s-217s. PubMed ID: 12743137
[TBL] [Abstract][Full Text] [Related]
18. Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer.
Kunos CA; Capala J; Kohn EC; Ivy SP
Front Oncol; 2019; 9():560. PubMed ID: 31297338
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
20. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
